Photo: Ida Marie Odgaard/Ritzau Scanpix/Sipa USA/Sipa via AP Images

FDA warns about com­pound­ed semaglu­tide-based drugs

The FDA has warned the pub­lic that com­pound­ed ver­sions of pop­u­lar GLP-1 drugs Ozem­pic and We­govy may not in­clude the same in­gre­di­ents as the pre­scrip­tion med­ica­tions, and that has raised ques­tions about their safe­ty and ef­fec­tive­ness.

The reg­u­la­tor said Tues­day it has re­ceived re­ports of ad­verse events re­lat­ed to com­pound­ed ver­sions of semaglu­tide, the ac­tive in­gre­di­ent in Ozem­pic and We­govy. Some prod­ucts be­ing mar­ket­ed as semaglu­tide con­tain the salt for­ma­tion of semaglu­tide, which is not con­sid­ered safe or ef­fec­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.